NCT07136077 2026-02-27
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07413146 2026-02-17
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial
Sun Yat-sen University
Phase NA Not yet recruiting
NCT06358430 2026-01-15
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04853017 2025-09-05
AMPLIFY-201
Elicio Therapeutics
Phase 1 Completed
NCT05534087 2024-11-29
CLAUDIA
Seoul National University Hospital
Phase 3 Recruiting
NCT05965479 2024-11-12
DECIPHER
University of Southampton
Phase 2 Recruiting
NCT06498752 2024-08-06
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06253650 2024-06-13
TRINITY
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT03189576 2023-05-26
Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
Tampere University Hospital
Phase NA Unknown
NCT05427669 2022-10-07
AFFORD
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT02314871 2019-03-13
Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4 Completed
NCT02900950 2016-09-15
MPM
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase NA Completed